First Experience with Omalizumab in a Child with Severe Persistent Asthma in Turkey: Case Report


Arga M., BAKIRTAŞ A. , TÜRKTAŞ İ. , Demirsoy M. S.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.30, sa.5, ss.1764-1767, 2010 (SCI İndekslerine Giren Dergi) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 30 Konu: 5
  • Basım Tarihi: 2010
  • Doi Numarası: 10.5336/medsci.2009-13351
  • Dergi Adı: TURKIYE KLINIKLERI TIP BILIMLERI DERGISI
  • Sayfa Sayıları: ss.1764-1767

Özet

Human monoclonal anti-IgE antibody (omalizumab) is recently recommended at the fifth step of international asthma guidelines for the treatment of patients older than 12 years of age who have severe persistent allergic asthma uncontrolled despite treatment with high-dose inhaled corticosteroid (>800 mu gr/day) in combination with a long-acting beta 2-agonist and oral leukotriene receptor antagonist and have serum total Ig E between 30-700 IU/ml. We started omalizumab as add-on treatment to a severe persistent asthmatic case who had two severe asthma attacks in the last three-month period, one of which was complicated with pneumomediastinium. This is the first experience with omalizumab in a child with severe asthma reported from our country. The first seven-month of omalizumab treatment resulted in significant improvements in quality of life and pulmonary functions as well as reductions in inhaled corticosteroid dose and daily symptom scores.